Key Points
- Royalty Pharma EVP Marshall Urist sold 4,126 shares at an average price of $57.10, generating proceeds of approximately $235,595. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
- RPRX opened at $56.66 and has a market capitalization of about $32.6 billion, with shares trading between $35.23 and $64.38 over the past year.
- Analysts maintain a broadly positive outlook, with a consensus “Buy” rating and a $61.29 target price. Royalty Pharma also pays a quarterly dividend of $0.235 per share, representing a 1.7% annualized yield.
Royalty Pharma PLC (NASDAQ:RPRX - Get Free Report) EVP Marshall Urist sold 4,126 shares of the company's stock in a transaction dated Monday, October 5th. The shares were sold at an average price of $57.10, for a total transaction of $235,594.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Marshall Urist also recently made the following trade(s):
- On Monday, September 28th, Marshall Urist sold 4,126 shares of Royalty Pharma stock. The shares were sold at an average price of $57.88, for a total transaction of $238,812.88.
Royalty Pharma Trading Down 0.9%
Shares of RPRX opened at $56.66 on Tuesday. The company has a debt-to-equity ratio of 0.88, a current ratio of 2.80 and a quick ratio of 2.80. Royalty Pharma PLC has a 1-year low of $35.23 and a 1-year high of $64.38. The stock has a market cap of $32.58 billion, a price-to-earnings ratio of 39.08, a price-to-earnings-growth ratio of 1.35 and a beta of 0.42. The firm has a 50 day simple moving average of $59.48 and a 200-day simple moving average of $55.03.
Royalty Pharma (NASDAQ:RPRX - Get Free Report) last posted its earnings results on Wednesday, August 5th. The biopharmaceutical company reported $1.32 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.27 by $0.05. Royalty Pharma had a return on equity of 30.01% and a net margin of 32.14%.The firm had revenue of $674.14 million for the quarter, compared to analyst estimates of $758.93 million. Equities analysts forecast that Royalty Pharma PLC will post 5.32 EPS for the current fiscal year.
Royalty Pharma Dividend Announcement
The business also recently declared a quarterly dividend, which was paid on Thursday, September 10th. Stockholders of record on Friday, August 14th were issued a $0.2350 dividend. This represents a $0.94 dividend on an annualized basis and a dividend yield of 1.7%. The ex-dividend date of this dividend was Friday, August 14th. Royalty Pharma's payout ratio is 64.83%.
Institutional Inflows and Outflows
A number of large investors have recently made changes to their positions in RPRX. Barton Investment Management purchased a new position in shares of Royalty Pharma in the 1st quarter worth about $905,000. Eventide Asset Management LLC lifted its stake in shares of Royalty Pharma by 41.5% in the 4th quarter. Eventide Asset Management LLC now owns 1,296,826 shares of the biopharmaceutical company's stock valued at $50,183,000 after purchasing an additional 380,337 shares in the last quarter. Calamos Wealth Management LLC acquired a new stake in Royalty Pharma during the 1st quarter worth approximately $3,762,000. Fieldview Capital Management LLC acquired a new stake in Royalty Pharma during the 4th quarter worth approximately $3,738,000. Finally, Monetta Financial Services Inc. purchased a new position in Royalty Pharma in the second quarter valued at approximately $1,682,000. Hedge funds and other institutional investors own 54.35% of the company's stock.
Analysts Set New Price Targets
RPRX has been the topic of a number of analyst reports. Weiss Ratings raised Royalty Pharma from a "buy (b-)" rating to a "buy (b)" rating in a research note on Monday, September 14th. Morgan Stanley reissued an "overweight" rating and issued a $65.00 target price on shares of Royalty Pharma in a research note on Thursday, August 6th. The Goldman Sachs Group restated a "buy" rating and issued a $66.00 target price on shares of Royalty Pharma in a report on Thursday, August 6th. Bank of America reaffirmed a "buy" rating on shares of Royalty Pharma in a research note on Wednesday, August 5th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Royalty Pharma from $58.00 to $62.00 and gave the stock an "overweight" rating in a report on Friday, August 7th. Eight analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Royalty Pharma currently has a consensus rating of "Buy" and a consensus target price of $61.29.
Get Our Latest Analysis on RPRX
Royalty Pharma Company Profile
(
Get Free Report)
Royalty Pharma plc is a biopharmaceutical royalty acquisition company that provides funding to life sciences companies in exchange for rights to future payments associated with approved or development-stage medicines. Its business model gives biotechnology and pharmaceutical companies access to capital while allowing Royalty Pharma to participate in the commercial success of therapies without directly developing or marketing them.
The company invests in royalties and other economic interests tied to a broad range of biopharmaceutical products, including treatments for cancer, rare diseases, immune disorders, diabetes and other chronic conditions.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
